Pharm-Olam Positioning for Growth Trajectory - Allucent
WEBJun 24, 2020 · Founded in 1994, with operations in 60 countries, this CRO goes the distance to create a healthier world through agile, innovative, and customized CRO solutions for Phase I-IV research. Learn how Pharm-Olam can help your study succeed at pharm-olam.com.
CATO SMS AND PHARM-OLAM MERGE TO CREATE GLOBAL BIOPHARMACEUTICAL ...
WEBJan 5, 2022 · Research Triangle Park, N.C. -based CATO SMS and Bracknell, U.K.-headquartered Pharm-Olam, are merging to create a global biopharmaceutical services organization uniquely positioned to serve...
Pharm-Olam, LLC - LinkedIn
WEBPharm-Olam, LLC | 40,284 followers on LinkedIn. Pharm-Olam is now Allucent. Purpose-built through the convergence of several leading providers including Pharm-Olam, Allucent is a global...
Pharm-Olam and CATO SMS are now Allucent - MassBio
WEBCARY, N.C., May 3, 2022 – Global biopharmaceutical services leader, CATO SMS, today unveiled its new name, Allucent, with bold branding to emphasize the company’s spotlight on serving the specialized needs of small and mid-sized biotech companies.
CATO SMS and Pharm-Olam Merge to Create Global ... - Allucent
WEBJan 5, 2022 · Research Triangle Park, N.C.-based CATO SMS and Bracknell, U.K.-headquartered Pharm-Olam are merging to create a global biopharmaceutical services organization uniquely positioned to serve small and …
CATO SMS is Now Allucent
WEBMay 2, 2022 · Rebranding comes after a series of strategic acquisitions, most recently Pharm-Olam. Company’s newly combined services address clinical development and consulting needs of small and mid-sized biotechs. New name unites worldwide experienced workforce in its singular mission.
US Department of Defense selects Pharm-Olam as CRO for …
WEBJan 19, 2021 · The JPEO-CBRND awarded Pharm-Olam a $36.3 million agreement to execute an adaptive, outpatient Phase II/III clinical trial of the monoclonal antibody, where adalimumab will be tested as a ...
US Department of Defense selects Pharm-Olam as CRO for ... - BioSpace
WEBJan 19, 2021 · The JPEO-CBRND awarded Pharm-Olam a $36.3 million agreement to execute an adaptive, outpatient Phase II/III clinical trial of the monoclonal antibody, where adalimumab will be tested as a treatment against the inflammatory response and associated complications brought on by COVID-19.
CATO SMS IS NOW ALLUCENT
WEBMay 3, 2022 · News Summary. - Rebranding comes after a series of strategic acquisitions, most recently Pharm-Olam. - Company’s newly combined services address clinical development and consulting needs of small and mid-sized biotechs. - New name unites worldwide experienced workforce in its singular mission.
Pharm-Olam IS NOW ALLUCENT - PharmiWeb.com
WEBMay 4, 2022 · Pharm-Olam IS NOW ALLUCENT. CARY, N.C., May 3, 2022 – Global biopharmaceutical services leader, CATO SMS, today unveiled its new name, Allucent with bold branding to emphasize the company’s spotlight on serving the specialized needs of small and mid-sized biotech companies.